Recent Updates
Recently added Catalysts
HRMY Positive Sentiment

Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium

Key Takeaway: Harmony Biosciences Holdings, Inc. will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on August 13, 2026. The event will be accessible via a webcast on their investor page. This participation underscores the company's dedication to developing therapies for rare neurological diseases.

Market Sentiment Analysis

POSITIVE FACTORS

  • Harmony Biosciences is actively engaging with the investment community.
  • Participation in the symposium highlights their commitment to innovation.
  • The company focuses on rare neurological diseases, addressing unmet medical needs.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+43%
120-day peak, hindsight
Typical move
3.7%
average across 2 past catalysts
Lead asset
Clemizole
Phase 3 · Lennox Gastaut Syndrome

Full Press Release Details

PLYMOUTH MEETING, Pa., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will participate in a fireside chat at the Piper Sandler Virtual CNS Symposium on Thursday, August 13, 2026, at 1:30 p.m. ET.
A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/.
About Harmony Biosciences Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
Harmony Biosciences Investor Contact: Brennan Doyle 484-566-3685 bdoyle@harmonybiosciences.com Harmony Biosciences Media Contact: Cate McCanless 202-641-6086 cmccanless@harmonybiosciences.com

Frequently Asked Questions

When is Harmony Biosciences participating in the symposium?

Harmony Biosciences will participate in the symposium on August 13, 2026.

How can I access the symposium webcast?

The webcast will be available on the investor page of Harmony Biosciences' website.

What is the focus of Harmony Biosciences?

Harmony Biosciences focuses on developing therapies for rare neurological diseases.

Who can be contacted for investor inquiries?

Brennan Doyle is the contact for investor inquiries at Harmony Biosciences.

Last updated: Aug 6, 2026